

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

---

In re:	:	Chapter 11
	:	
PURDUE PHARMA L.P., <i>et al.</i> ,	:	Case No. 19-23649 (RDD)
	:	
Debtors. <sup>1</sup>	:	(Jointly Administered)
	:	

---

**NOTICE OF TWENTY-FIRST MONTHLY FEE STATEMENT OF JONES DAY FOR  
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT  
OF EXPENSES INCURRED AS SPECIAL COUNSEL TO THE DEBTORS  
FOR THE PERIOD FROM JULY 1, 2021 THROUGH JULY 31, 2021**

---

<b>Name of Applicant:</b>	Jones Day
<b>Authorized to Provide Services to:</b>	Purdue Pharma L.P., <i>et al.</i>
<b>Date of Retention:</b>	December 20, 2019, <i>nunc pro tunc</i> to September 15, 2019
<b>Period for Which Compensation and Expense Reimbursement is Sought:</b>	July 1, 2021 through July 31, 2021
<b>Amount of Compensation Requested (after 13% discount):</b>	\$304,456.94
<b>Less 20% Holdback</b>	\$60,891.39
<b>Net of Holdback:</b>	\$243,565.55
<b>Amount of Expense Reimbursement Requested:</b>	\$89.84
<b>Total Compensation (Net of Holdback) and Expense Reimbursement Requested:</b>	\$243,655.39
<b>This is a</b>	<u>  X  </u> Monthly <u>      </u> Interim <u>      </u> Final Fee Statement

---

<sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

In accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals*, entered on November 21, 2019 [Docket No. 529] (the “Interim Compensation Order”),<sup>2</sup> Jones Day hereby submits this twenty-first monthly fee statement (the “Twenty-First Monthly Fee Statement”), seeking compensation for services rendered and reimbursement of expenses incurred as special counsel to the Debtors, for the period from July 1, 2021 through July 31, 2021 (the “Twenty-First Monthly Fee Period”). By this Twenty-First Monthly Fee Statement, and after taking into account certain voluntary discounts,<sup>3</sup> Jones Day seeks payment in the amount of \$243,655.39 which comprises (i) 80% of the total amount of compensation sought for actual and necessary services rendered during the Twenty-First Monthly Fee Period and (ii) reimbursement of 100% of actual and necessary expenses incurred in connection with such services.

#### **SERVICES RENDERED AND EXPENSES INCURRED**

1. Attached hereto as **Exhibit A** is a summary of Jones Day professionals by individual, setting forth the (a) name and title of each individual who provided services during the Twenty-First Monthly Fee Period, (b) aggregate hours spent by each individual, (c) hourly billing rate for each such individual at Jones Day’s then-current billing rates, (d) amount of fees earned by each Jones Day professional, and (e) year of bar admission for each attorney. The blended

---

<sup>2</sup> Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Interim Compensation Order.

<sup>3</sup> The total amount sought for fees reflects application of a 13% discount on all fees, pursuant to an agreed practice between Jones Day and the Debtors which was implemented prior to the Petition Date (totaling \$45,493.57 for the Twenty-First Monthly Fee Period). In addition, as part of the discounted fee arrangement, Jones Day agreed to charge the Debtors the previous year’s billable rates for the periods during which services were rendered (*i.e.*, for 2021, Jones Day is using 2020 billable rates in calculating amounts due for legal services performed).

hourly billing rate of Jones Day timekeepers during the Twenty-First Monthly Fee Period is approximately \$716.37.<sup>4</sup>

2. Attached hereto as **Exhibit B** is a summary of the services rendered and compensation sought, by project category, for the Twenty-First Monthly Fee Period.

3. Attached hereto as **Exhibit C** is a summary of expenses incurred and reimbursement sought, by expense type, for the Twenty-First Monthly Fee Period

4. Attached hereto as **Exhibit D** are copies of Jones Day invoices for the Twenty-First Monthly Fee Period.<sup>5</sup>

### NOTICE AND OBJECTION PROCEDURES

5. Notice of this Twenty-First Monthly Fee Statement shall be given to the following parties (collectively, the “Notice Parties”): (i) Purdue Pharma L.P., 201 Tresser Blvd, Stamford, CT 06901, Attn: Jon Lowne, Email: Jon.Lowne@pharma.com; (ii) counsel to the Debtors, Davis Polk & Wardwell LLP, 450 Lexington Avenue, New York, New York 10017, Attn: Christopher Robertson and Dylan Consla, Email: christopher.robertson@davispolk.com, dylan.consla@davispolk.com; (iii) counsel to the Committee: (a) Akin Gump Strauss Hauer & Feld LLP, One Bryant Park, Bank of America Tower, New York, NY 10036-6745, Attn: Arik Preis, Email: apreis@akingump.com and Sara L. Brauner, Email: sbrauner@akingump.com; and (b) Cole Schotz, P.C., 500 Delaware Avenue, Suite 1410, Wilmington, Delaware 19801, Attn: Justin R. Alberto, Email: jalberto@coleschotz.com; (iv) the Office of the United States Trustee, U.S. Federal Office Building, 201 Varick Street, Suite 1006, New York, New York 10014, Attn: Paul K. Schwartzberg, Email: Paul.Schwartzberg@usdoj.gov; and (v) the fee examiner, Bielli &

---

<sup>4</sup> The blended rate is comprised of all Jones Day timekeepers who provided services during the Twenty-First Monthly Fee Period.

<sup>5</sup> The time records included in **Exhibit C** have been redacted to protect privileged information.

Klauder, LLC, 1204 N. King Street, Wilmington, DE 19801, Attn: David M. Klauder, Esq.,  
Email: dklauder@bk-legal.com.

6. Objections to this Twenty-First Monthly Fee Statement, if any, must be served via electronic mail upon Jones Day, 250 Vesey Street, New York, NY, 10281, Attn: Anna Kordas (akordas@jonesday.com) no later than November 4, 2021 at 12:00 p.m. (prevailing Eastern Time) (the “Objection Deadline”), setting forth the nature of the objection and the specific amount of fees at issue.

7. If no objections to this Twenty-First Monthly Fee Statement are received by the Objection Deadline, the Debtors shall promptly pay Jones Day 80% of the fees and 100% of expenses identified in this Twenty-First Monthly Fee Statement.

8. To the extent that an objection to this Twenty-First Monthly Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Twenty-First Monthly Fee Statement to which the objection is directed and promptly pay the remainder of the fees in the percentages set forth above. To the extent such an objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing.

*[The remainder of this page has been intentionally left blank]*

**NO PRIOR REQUEST**

9. No prior request for the relief sought in this Twenty-First Monthly Fee Statement has been made to this or any other court.

Dated: October 21, 2021  
New York, NY

/s/ Anna Kordas  
JONES DAY  
John J. Normile  
Anna Kordas  
250 Vesey Street  
New York, NY 10281  
Telephone: (212) 326-3939  
Facsimile: (212) 755-7306  
Email: jjnormile@jonesday.com  
akordas@jonesday.com

– and –

Chané Buck  
4655 Executive Drive, Suite 1500  
San Diego, CA 92121  
Telephone: (858) 314-1158  
Facsimile: (844) 345-3178  
Email: cbuck@jonesday.com

*Special Counsel to the Debtors and  
Debtors in Possession*

**EXHIBIT A**

**COMPENSATION BY PROFESSIONAL PERSON**

**JONES DAY**  
**PROFESSIONAL PERSON SUMMARY**  
**JULY 1, 2021 – JULY 31, 2021**

<u>NAME</u>	<u>YEAR OF ADMISSION</u>	<u>RATE</u>	<u>WITH 13% DISCOUNT</u>	<u>HOURS</u>	<u>AMOUNT</u>
<b><u>PARTNER</u></b>					
Anthony C. Chen	1993	\$1,000.00	\$870.00	14	\$14,000.00
Matthew W. Johnson	2007	\$850.00	\$739.50	0.3	\$255.00
Gaspar J. LaRosa	2002	\$1,125.00	\$978.75	25.2	\$28,350.00
Christopher Morrison	2001	\$1,025.00	\$891.75	2.7	\$2,767.50
Dan T. Moss	2007	\$1,075.00	\$935.25	0.2	\$215.00
John J. Normile	1989	\$1,275.00	\$1,109.25	57.3	\$71,625.00
<b>TOTAL PARTNER:</b>				<b>99.7</b>	<b>\$117,212.50</b>
<b><u>COUNSEL</u></b>					
Kelsey I. Nix	1988	\$1,225.00	\$1,065.75	76.3	\$90,034.00
<b>TOTAL COUNSEL:</b>				<b>76.3</b>	<b>\$90,034.00</b>
<b><u>ASSOCIATE</u></b>					
Chané Buck	2017	\$575.00	\$500.25	8.8	\$5,060.00
Kevin V. McCarthy	2016	\$725.00	\$630.75	111.2	\$79,508.00
Adam M. Nicolais	2017	\$675.00	\$587.25	49.7	\$32,553.50
<b>TOTAL ASSOCIATE:</b>				<b>169.7</b>	<b>\$117,121.50</b>
<b><u>PARALEGAL &amp; STAFF</u></b>					
Jason J. Darensbourg	N/A	\$350.00	\$304.50	12.3	\$4,305.00
Marguerite Melvin	N/A	\$400.00	\$348.00	1.1	\$440.00
Brendan Y. Keenan	N/A	\$250.00	\$217.50	1.0	\$250.00
Timothy E. Solomon	N/A	\$400.00	\$348.00	8.0	\$3,200.00
Shuheng Li	N/A	\$325.00	\$282.75	21.2	\$6,890.00
Morris Jackson	N/A	\$175.00	\$152.25	1.7	\$297.50
Bonnie Zhu	N/A	\$300.00	\$261.00	34	\$10,200.00
<b>TOTAL LEGAL SUPPORT:</b>				<b>79.3</b>	<b>\$25,582.50</b>
<b>TOTAL:</b>				<b>425</b>	<b>\$349,950.50</b>

**EXHIBIT B**

**COMPENSATION BY PROJECT CATEGORY**

**JULY 1, 2021 – JULY 31, 2021**

<b>Project Category</b>	<b>Total Hours</b>	<b>Total Fees</b>
Collegium Pharmaceuticals	303.6	\$274,949.00
Strategic Corporate Advice	15.6	\$11,944.50
Retention Matters	17.2	\$14,625.00
Accord Healthcare Inc.	19.4	\$17,342.00
Article 76 Patent Linkage Litigation	69.2	\$31,090.00
<b>TOTAL</b>	<b>425</b>	<b>\$349,950.50</b>
<b>13% DISCOUNT</b>		<b>\$45,493.57</b>
<b>TOTAL FEES</b>		<b>\$304,456.94</b>



**EXHIBIT C**

**EXPENSE SUMMARY  
JULY 1, 2021 – JULY 31, 2021**

<b>Expense Category</b>	<b>Total Expenses</b>
Mailing Charges	\$89.84
<b>TOTAL</b>	<b>\$89.84</b>

**EXHIBIT D**

**TIME DETAIL**

**JONES DAY**

**New York Office**  
250 Vesey Street  
New York, NY 10281-1047  
(212) 326-3939  
**Federal Identification Number: 34-0319085**

October 15, 2021

305158.000003  
Invoice: 210903857

Purdue Pharma L.P.  
Attention: Bruce J. Koch, Esq.  
Chief Patent Counsel  
One Stamford Forum  
Stamford, CT 06901

For legal services rendered for the period through July 31, 2021:

Article 76 Patent Linkage Litigation	USD	31,090.00
Less 13% Fee Discount		<u>(4,041.70)</u>
Total Billed Fees	USD	27,048.30
<b>TOTAL</b>	<b>USD</b>	<b><u>27,048.30</u></b>

Pg 12 of 41  
**JONES DAY**

305158.000003

Page: 2

October 15, 2021

Article 76 Patent Linkage Litigation

Invoice: 210903857

## Timekeeper/Fee Earner Summary

	<i>Hours</i>	<i>Rate</i>	<i>Amount</i>
Partner			
A C Chen	14.00	1,000.00	14,000.00
Specialist			
S Li	21.20	325.00	6,890.00
B Zhu	34.00	300.00	10,200.00
	<hr/>		<hr/>
<b>Total</b>	<b>69.20</b>	<b>USD</b>	<b>31,090.00</b>

Pg 13 of 41  
**JONES DAY**

305158.000003

Page: 3

October 15, 2021

Article 76 Patent Linkage Litigation

Invoice: 210903857

## Fee Detail

<i>Date of Service</i>	<i>Timekeeper/Fee Earner Name</i>	<i>Hours</i>
07/23/21	A C Chen	2.50
	Call [REDACTED] (.5); review [REDACTED] (1.0); verify [REDACTED] (.4); discuss with Shuheng Li (.6).	
07/25/21	A C Chen	2.00
	Review [REDACTED] (1.3); discuss with Shuheng Li about [REDACTED] (.7).	
07/26/21	A C Chen	3.50
	Call with Richard Inz and Shuheng Li about [REDACTED] (1.1); review memo [REDACTED] (1.7); discuss [REDACTED] (.7).	
07/26/21	S Li	5.50
	Discuss with Tony Chen of Jones Day regarding [REDACTED] (.7); review and analyze [REDACTED] (.3); investigate [REDACTED] (1.0); review [REDACTED] (.2); discuss with Yan Zhu of Jones Day regarding [REDACTED] (.2); prepare [REDACTED] (.6); discuss [REDACTED] (.4); prepare [REDACTED] (.2); review and revise [REDACTED] (.8); attend the meeting [REDACTED] (1.1).	
07/26/21	B Zhu	7.00
	[REDACTED]	
07/27/21	A C Chen	1.50
	Review [REDACTED] (.5); communicate with Richard Inz about [REDACTED] (.5); call [REDACTED] (.5).	
07/27/21	S Li	5.50
	Review and analyze [REDACTED] (3.0); discuss with Yan Zhu regarding [REDACTED] (.8); conducting the analysis [REDACTED] (.8); preparing [REDACTED] (1.7).	
07/28/21	A C Chen	1.00
	Review [REDACTED]	
07/28/21	S Li	3.00
	Attention to email from Richard Inz [REDACTED] (.4); review and analyze [REDACTED] (2.0); discuss with Tony Chen, Yan Zhu regarding [REDACTED] (.6).	
07/28/21	B Zhu	5.00
	[REDACTED]	

**JONES DAY**

305158.000003

Page: 4

October 15, 2021

Article 76 Patent Linkage Litigation

Invoice: 210903857

<i>Date of Service</i>	<i>Timekeeper/Fee Earner Name</i>	<i>Hours</i>
07/29/21	A C Chen	3.50
	Review and revise [REDACTED] [REDACTED] (2.2); WebEx call [REDACTED] [REDACTED] (.8); discuss with Shuheng Li and Yan Zhu about [REDACTED] [REDACTED] (.5).	
07/29/21	S Li	4.20
	Discuss with Tony Chen, Yan Zhu regarding [REDACTED] [REDACTED] (.8); review [REDACTED] (1.4); [REDACTED] (.6); discuss with Yan Zhu regarding [REDACTED] [REDACTED] (1.0); correspondence with Tony Chen regarding the same (.4).	
07/29/21	B Zhu	8.00
	[REDACTED]	
07/30/21	S Li	3.00
	Discuss with Yan Zhu and Tony Chen regarding [REDACTED] [REDACTED] (1.0); review and revise [REDACTED] (2.0).	
07/30/21	B Zhu	14.00
	[REDACTED] [REDACTED] (.8); [REDACTED] (6.0); prepare [REDACTED] (7.2).	
	<b>Total</b>	<b>69.20</b>

**JONES DAY**

**New York Office**  
250 Vesey Street  
New York, NY 10281-1047  
(212) 326-3939  
**Federal Identification Number: 34-0319085**

October 15, 2021

305158.610005  
Invoice: 210903858

Purdue Pharma L.P.  
Attention: Bruce J. Koch, Esq.  
Chief Patent Counsel  
One Stamford Forum  
Stamford, CT 06901

For legal services rendered for the period through July 31, 2021:

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals	USD	274,949.00
Less 13% Discount		<u>(35,743.37)</u>
Total Billed Fees	USD	239,205.63

**Disbursement & Charges Summary**

Federal Express Charges	89.84	
	USD	<u>89.84</u>
<b>TOTAL</b>	<b>USD</b>	<b><u><u>239,295.47</u></u></b>

Please remit payment to:

**ACH Transfer (preferred)**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089

**Wire Transfer**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089  
Swift Code: CITIUS33

Pg 16 of 41  
**JONES DAY**

305158.610005

Page: 2

October 15, 2021

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 210903858

## Timekeeper/Fee Earner Summary

	<i>Hours</i>	<i>Rate</i>	<i>Amount</i>
Partner			
M W Johnson	0.30	850.00	255.00
G J Larosa	25.20	1,125.00	28,350.00
C M Morrison	2.70	1,025.00	2,767.50
J J Normile	41.30	1,250.00	51,625.00
Of Counsel			
K I Nix	76.00	1,180.00	89,680.00
Associate			
K McCarthy	90.90	715.00	64,993.50
A M Nicolais	45.10	655.00	29,540.50
Paralegal			
J J Darensbourg	11.40	350.00	3,990.00
T E Solomon	8.00	400.00	3,200.00
Librarian			
M M Jackson	1.70	175.00	297.50
B Y Keenan	1.00	250.00	250.00
<b>Total</b>	<b>303.60</b>	<b>USD</b>	<b>274,949.00</b>



**JONES DAY**

305158.610005

Page: 3

October 15, 2021

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 210903858

## Fee Detail

<i>Date of Service</i>	<i>Timekeeper/Fee Earner Name</i>	<i>Hours</i>
07/01/21	J J Darensbourg Manage/prepare key case materials for review by J Normile and G LaRosa.	1.20
07/01/21	M W Johnson Discuss [REDACTED] with J. Normile.	0.30
07/01/21	G J Larosa Communicate (in firm) regarding [REDACTED] (1.0); and reviewed related pleadings(1.0).	2.00
07/01/21	K McCarthy Prepare for and participate in teleconference with A. Nicolais and paralegal team regarding document discovery and other case administrative tasks (0.7); coordinate preparation of key document binders (0.5); attention to internal, client, and opposing counsel correspondence regarding third-party document and sample productions (0.8); draft/revise third-party subpoenas and communicate with A. Nicolais regarding same (0.8); [REDACTED] (0.8); review/analyze [REDACTED] (0.4).	4.00
07/01/21	A M Nicolais Edits/revisions to draft subpoena to Johnson Matthey (.5); call with K. McCarthy re Collegium action items (.5); call with paralegals and K. McCarthy re actions items (.5); communication in firm with P. Hendler re [REDACTED] (.4); reviewing opposing counsel letter re discovery (.4); communication with T. Solomon re Collegium action items (.2).	2.50
07/01/21	K I Nix Work regarding [REDACTED] (2.2); [REDACTED] (.5); [REDACTED] (.7).	3.40
07/01/21	J J Normile [REDACTED] (.80); [REDACTED] (1.0); various correspondence regarding [REDACTED] (1.0); various correspondence and teleconferences regarding [REDACTED] (.50).))	3.30
07/01/21	T E Solomon Review case database, assemble key documents and draft index for binders for J. Normile and G. LaRosa per K. McCarthy's instructions.	5.00
07/02/21	G J Larosa Plan and prepare for [REDACTED]	2.00
07/02/21	K McCarthy Review/analyze opposing counsel correspondence regarding discovery issues (0.7); coordinate collection of cited documents (0.3); review/analyze cited documents and draft/revise internal summary regarding same (1.0); [REDACTED] (2.0).	4.00

Pg 18 of 41  
**JONES DAY**

305158.610005

Page: 4

October 15, 2021

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 210903858

07/02/21 A M Nicolais 1.90  
Meeting with K. Nix and D. Rosen regarding [REDACTED] (.7); plan/prepare re same (.3); reviewing prior productions regarding [REDACTED] (.7); communication in firm with K. Nix re same (.2).

07/02/21 K I Nix 3.70  
Teleconference with D. Rosen and A. Nicolais regarding [REDACTED] (.7), preparation for and follow up regarding same (1.5); worked on [REDACTED] (1.5).

07/02/21 T E Solomon 3.00  
Prepare and send Key Documents binders to J. Normile and G. LaRosa for their review (2.00); review discovery materials on case database and forward requested documents to K. McCarthy for his review (1.00).

07/06/21 J J Darensbourg 1.10  
Manage excel files concerning [REDACTED] for review by D. Rosen.

07/06/21 G J Larosa 2.00  
Communicate (in firm) regarding [REDACTED] and reviewed materials in preparation for same.

07/06/21 K McCarthy 5.00  
Prepare for and participate in teleconference with [REDACTED] (0.8); prepare for and participate in teleconference with J. Normile and G. LaRosa regarding case strategy (0.9); prepare for and participate in teleconference with B. Koch regarding [REDACTED] (0.7); draft/revise [REDACTED] and communicate internally regarding same (0.6) review/analyze recent discovery correspondence and draft internal summary of same (1.5); attention to opposing counsel and client correspondence regarding 434 patent contentions (0.5).

07/06/21 A M Nicolais 4.10  
Drafting Collegium joint status update re bankruptcy (.3); communication in firm re same (.1). reviewing [REDACTED] (.8); communication in firm and collection of documents re [REDACTED] (.7); edits/revisions to RFAs (.3); edits/revisions to supplement rog responses re [REDACTED] (.4); communications with K. McCarthy re action items (.5); meeting with J. Normile and G. LaRosa re Collegium action items (.5); meeting with B. Koch re [REDACTED] (.5).

07/06/21 K I Nix 5.00  
Worked on supplemental response to [REDACTED] and e-mails with J. Normile and A. Nicolais regarding same (.6); studied Collegium responses to interrogatories regarding [REDACTED] and work regarding same (1.4); studied C. Pinah letter regarding discovery issues [REDACTED] (.8); work regarding proposals for supplemental [REDACTED] (.2); considered issue of additional written discovery on [REDACTED] (.5); work regarding [REDACTED] (.4); e-mails and teleconference with D. McDuff regarding [REDACTED] (.5); e-mails with [REDACTED] (.6).

07/06/21 J J Normile 4.80  
Preparation for and participation in team teleconference regarding various outstanding discovery issues (.80); [REDACTED] (1.5); preparation of status update to the SDNY including various correspondence with K. Barrett and O. Langer (1.5); [REDACTED] (1.0).

**JONES DAY**

305158.610005

Page: 5

October 15, 2021

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 210903858

07/07/21	J J Darensbourg	0.30
Manage new updated [REDACTED] from D Rosen for attorney review.		
07/07/21	K McCarthy	3.00
Draft/revise supplemental discovery requests and responses and communicate with P. Hendler and A. Nicolais regarding same (2.0); attention to [REDACTED] and communicate internally regarding same (0.5); attention to case files and correspondence regarding recent discovery letter (0.5).		
07/07/21	A M Nicolais	4.80
Updating [REDACTED] (.5); edits/revisions to second set of RFAs (.5); review/analyze research re [REDACTED] (.5); meeting with D. Sloan re [REDACTED] (.4); research re [REDACTED] (1.2); drafting summary re same (.7); communication in firm re supplemental rogs/rfps and reviewing prior requests re same (.5); communication with K. McCarthy re same (.2); drafting agenda re discovery meeting (.3).		
07/07/21	K I Nix	5.20
Teleconference with [REDACTED] (1.2); e-mails with J. Normile and K. McCarthy regarding [REDACTED] and response to C. Pinahs July 1, 2021 letter, including interrogatories regarding Collegium rebates (.8); worked on research regarding [REDACTED] (2.5); studied [REDACTED] (.7).		
07/07/21	J J Normile	3.30
Continued review and revision of supplemental discovery requests and correspondence with A. Nicolais and K. McCarthy regarding same (1.0); attention to preparation of response to Collegium's 7/1/21 discovery letter and review of summary of proposed supplemental discovery (1.8); attention to various issues relating to [REDACTED] (.50).		
07/08/21	J J Darensbourg	1.90
Review trial transcript document production to Defendant for possible further production to clear up discovery issues.		
07/08/21	G J Larosa	2.00
Communicate (in firm) and with client regarding [REDACTED]		
07/08/21	K McCarthy	7.00
Prepare for and participate in various teleconferences with client and co-counsel regarding [REDACTED] (2.2); draft/revise [REDACTED] and communicate internally, with co-counsel, and with client regarding same (2.6); [REDACTED] (1.2); review/analyze legal research regarding certain discovery disputes (1.0).		
07/08/21	A M Nicolais	4.00
Meeting with P. Hendler and K. McCarthy re discovery requests (.5); meeting with Collegium internal team re discovery supplemental requests and letter (.5); [REDACTED] (.5); drafting additional RFPs/ROGs/RFA (1.9); communication in firm with P. Hendler and K. McCarthy re same (.6).		
07/08/21	K I Nix	4.20
Teleconference with S. Anwar regarding further legal research regarding [REDACTED] (.9); work regarding [REDACTED] (.5); teleconference with [REDACTED]		

Pg 20 of 41  
**JONES DAY**

305158.610005

Page: 6

October 15, 2021

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 210903858

D. Rosen regarding [REDACTED] (.6); studied summary of [REDACTED] (2.2).

07/08/21 J J Normile 4.10  
Preparation for and participation in teleconference with K. McCarthy, G. LaRosa, A. Nicolais and P. Hendler regarding [REDACTED] (.80); preparation for and participation in teleconference with [REDACTED] (.80); [REDACTED] (1.5); [REDACTED] (1.0).

07/09/21 B Y Keenan 1.00  
Research case law on [REDACTED]

07/09/21 G J Larosa 2.00  
Review/analyze draft discovery requests and conferred in firm regarding same.

07/09/21 K McCarthy 6.50  
Draft/revise supplemental discovery requests and finalize and serve (2.3), review/analyze Collegium discovery letter and referenced prior discovery requests, correspondence, and disclosures, and communicate internally and with co-counsel regarding same (3.1); draft/revise email response to Collegium regarding same (0.6); review/analyze Collegium's supplemental discovery requests (0.5).

07/09/21 C M Morrison 0.60  
Review and revise [REDACTED]

07/09/21 K I Nix 3.20  
E-mails and teleconferences with [REDACTED] ((e-mails to J. Normile and K. McCarthy regarding [REDACTED] (2.5); final review of revised draft interrogatories to Collegium (.7).

07/09/21 J J Normile 2.50  
Review and revise [REDACTED] (1.5); [REDACTED] (1.0).

07/11/21 K I Nix 1.20  
Studied Collegium's interrogatories, requests for admissions and document requests directed to [REDACTED] and began formulating responses and positions regarding same.

07/12/21 J J Darensbourg 0.80  
Manage [REDACTED] for review by K McCarthy.

07/12/21 M M Jackson 0.20  
Retrieve article using the web for A. Nicolais.

07/12/21 G J Larosa 1.00  
Review/analyze discovery requests and conferred in firm and with client regarding case strategy.

Pg 21 of 41  
**JONES DAY**

305158.610005

Page: 7

October 15, 2021

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 210903858

07/12/21 K McCarthy 3.50  
Prepare for and participate in weekly client teleconference regarding [REDACTED] (0.6); review/analyze Collegium's July 9, 2021 supplemental discovery requests (1.1); attention to internal correspondence regarding [REDACTED] (0.6); draft/revise [REDACTED] and communicate internally regarding same (0.6); prepare for and participate in internal teleconference with K. Nix regarding [REDACTED] issues and Collegium's supplemental discovery requests (0.6).

07/12/21 A M Nicolais 2.00  
Communication in firm with P. Hendler re [REDACTED] (.4); reviewing Collegium supplemental RFPs/ROGS/RfAs (.8); meeting with K. Nix and K. McCarthy re responses to [REDACTED] (.8).

07/12/21 K I Nix 4.40  
Studied [REDACTED] (.8); teleconferences with K. McCarthy and A. Nicolais regarding searching [REDACTED] (.6); work regarding [REDACTED] (2.0); studied [REDACTED] (1.0).

07/12/21 J J Normile 3.00  
Preparation for and participation in weekly team teleconference including B. Koch, R. Silbert, R. Kreppel, R. Inz, P. Hendler and K. McCarthy (1.0); ((review [REDACTED] and various emails regarding same)) (1.0); ((attention to [REDACTED])) (1.0).

07/13/21 K McCarthy 5.50  
Prepare for and participate in teleconference with P. Hendler and A. Nicolais regarding discovery issues (1.1); [REDACTED] (1.7); attention to [REDACTED] (0.8); review/analyze Collegium's produced documents regarding [REDACTED] and communicate with K. Nix and A. Nicolais regarding same (1.2); draft/ [REDACTED] and communicate with client regarding same (0.4); attention to case files and correspondence (0.3).

07/13/21 A M Nicolais 2.30  
Meeting with P. Hendler and K. McCarthy re discovery requests (1.0); review/analyze Collegium document production re [REDACTED] (.5); drafting correspondence with K. Nix re same (.4); [REDACTED] (.3); communication in firm with P. Hendler re same (.1).

07/13/21 K I Nix 3.80  
Work regarding [REDACTED] including studied summary of legal research and cases (1.1); and conferred with S. Anwar regarding preparation and outline of research memorandum for client summarizing research and conclusions (.7); work regarding analysis of [REDACTED] including e-mails with K. McCarthy and A. Nicolais (1.2); studied [REDACTED] (.8).

07/13/21 J J Normile 2.30  
[REDACTED] (1.5); attention to finalizing joint statement to the SDNY (.80).

07/14/21 G J Larosa 1.00  
Communicate (in firm) regarding [REDACTED] and discovery and reviewed related materials.

**JONES DAY**

305158.610005

Page: 8

October 15, 2021

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 210903858

07/14/21	K McCarthy	3.00
Draft/revise responses to Collegium's July 9 interrogatories (1.7); and attention to related case correspondence regarding Collegium's other discovery requests (0.4); draft/revise [REDACTED] and address internal, co-counsel, and client edits to same (0.6); attention to [REDACTED] and related materials (0.3).		
07/14/21	A M Nicolais	0.30
Communication in firm with K. McCarthy re action items (.3).		
07/14/21	K I Nix	1.60
Studied updated spreadsheets from D. Rosen (1.0); work regarding [REDACTED] and legal research by S. Anwar (.6).		
07/14/21	J J Normile	0.80
[REDACTED] and review of correspondence regarding same)).		
07/15/21	J J Darensbourg	0.40
Manage shared database for attorneys of correspondence regarding [REDACTED]		
07/15/21	G J Larosa	1.00
Communicate (in firm) regarding [REDACTED] (.4); and reviewed related draft materials (.6).		
07/15/21	A M Nicolais	2.00
Drafting RFP responses to Collegium's 4th set of RFPs (1.1); reviewing research re [REDACTED] (.9).		
07/15/21	K I Nix	1.70
Work regarding [REDACTED] (.3); studied [REDACTED] (.4); attention to search of Collegium production for [REDACTED] (1.0).		
07/15/21	J J Normile	0.50
Attention to [REDACTED]		
07/16/21	A M Nicolais	0.30
Final review and preparing final versions of claim terms for construction for service (.3).		
07/16/21	K I Nix	3.50
Work regarding [REDACTED]		
07/16/21	J J Normile	0.80
Attention to various [REDACTED]		
07/18/21	K I Nix	1.40
Studied [REDACTED]		



Pg 23 of 41  
**JONES DAY**

305158.610005

Page: 9

October 15, 2021

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 210903858

07/19/21	J J Darensbourg	0.20
	Manage [REDACTED] for review by K Nix.	
07/19/21	G J Larosa	1.00
	Communicate (in firm) and with client regarding [REDACTED].	
07/19/21	K McCarthy	3.40
	Prepare for and participate in client teleconference regarding [REDACTED] (0.9); perform legal research [REDACTED] and communicate internally regarding same (1.7); draft/revise response to Collegium's discovery letter (0.5); attention to case file and correspondence (0.3).	
07/19/21	K I Nix	3.30
	Teleconference with D. Rosen and preparation for same (.3); e-mails with K. McCarthy regarding response to Collegium's July 1 letter and regarding searching Collegium production for [REDACTED] (1.0); studied [REDACTED] (2.0).	
07/19/21	J J Normile	2.10
	Preparation for and participation in teleconference with B. Koch, P. Hendler and K. McCarthy regarding [REDACTED] (.80); preparation for and participation in weekly team teleconference with B. Koch, R. Silbert, R. Inz, P. Hendler, A. Nicolais and K. McCarthy (.50); review of correspondence from O. Langer and P. Hendler regarding various claim construction issues (.80).	
07/20/21	G J Larosa	1.50
	Plan and prepare for [REDACTED]	
07/20/21	K McCarthy	3.50
	Review/analyze certain [REDACTED] (0.9) and communicate [REDACTED] (0.6); prepare for and participate in meet and confer with opposing counsel regarding claim construction issues (1.0); perform legal research [REDACTED] and prepare for and participate in teleconference with P. Hendler and A. Nicolais regarding same (1.0).	
07/20/21	A M Nicolais	6.10
	[REDACTED] (.3); researching [REDACTED] (1.6); drafting summary re same (.5); communication with K. McCarthy re Collegium action items (.3); meet and confer re claim construction (.4); researching [REDACTED] (1.1); drafting summary re same (.5); researching [REDACTED] (1.0); drafting summary re same (.4).	
07/20/21	K I Nix	2.80
	Teleconference [REDACTED] and preparation and follow-up regarding same (1.5); teleconference with S. Anwar regarding draft memorandum summarizing legal research on [REDACTED] and work regarding same (1.3).	
07/20/21	J J Normile	2.10
	Preparation for and participation in meet and confer with counsel for Collegium on claim construction issues (.30); review of [REDACTED] (.80); [REDACTED] (1.0).	

Pg 24 of 41  
**JONES DAY**

305158.610005

Page: 10

October 15, 2021

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 210903858

07/21/21	J J Darensbourg	0.30
	Manage shared database for attorneys of [REDACTED] and opposing counsel regarding [REDACTED]	
07/21/21	G J Larosa	2.00
	Review/analyze [REDACTED] and conferred in firm regarding same (.8); and attention to draft opening Markman brief and conferred with co-counsel regarding same (1.2).	
07/21/21	K McCarthy	5.00
	Draft/revise [REDACTED] (1.4); perform legal research in support of same (1.7); review scheduling order and communicate internally regarding [REDACTED] (0.8); attention to opposing counsel correspondence regarding updated proposed claim terms and constructions following meet and confer (0.5); attention to internal and expert correspondence regarding [REDACTED] (0.6).	
07/21/21	C M Morrison	0.50
	Review and revise [REDACTED]	
07/21/21	A M Nicolais	0.80
	Meeting with K. Nix [REDACTED] (.8).	
07/21/21	K I Nix	3.30
	Video meeting with D. Rosen, W. Shank, K. Christiansen and A. Nicolais regarding third-party proposals, rebates and negotiations, and follow-up regarding same (1.6); studied e-mails regarding proposed claim constructions (.4); work regarding [REDACTED] (.7); work regarding [REDACTED] (.6).	
07/21/21	J J Normile	1.50
	[REDACTED]	
07/22/21	J J Darensbourg	1.40
	Manage/prepare exhibits for [REDACTED]	
07/22/21	G J Larosa	1.50
	Communicate (other outside counsel) with Opposing counsel regarding claim construction and attention to related briefing.	
07/22/21	K McCarthy	4.50
	Draft/revise [REDACTED] (2.5); perform legal and factual research in support of same (1.1); prepare for and participate in meet and confer with opposing counsel regarding claim construction issues (0.9).	
07/22/21	C M Morrison	0.60
	Confer [REDACTED] (.3); confer with Collegium regarding expert reports (.3).	
07/22/21	A M Nicolais	0.80
	Communication in firm with K. McCarthy (.3); [REDACTED] (.5).	



Pg 25 of 41  
**JONES DAY**

305158.610005

Page: 11

October 15, 2021

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 210903858

07/22/21	K I Nix	3.30
	Studied [REDACTED] [REDACTED] (1.5); studied [REDACTED] from S. Anwar regarding [REDACTED] (1.2); work regarding [REDACTED] (.6).	
07/22/21	J J Normile	0.80
	Review and revise [REDACTED] [REDACTED]	
07/23/21	G J Larosa	1.20
	Draft/revise [REDACTED] and conferred in firm regarding same.	
07/23/21	K McCarthy	3.50
	Draft/revise [REDACTED] (1.0); [REDACTED] [REDACTED] (.5); and finalize brief and exhibits for filing (1.0); review/analyze Collegium's opening claim construction brief (0.6); attention to case files and case correspondence (0.4).	
07/23/21	C M Morrison	1.00
	Review and file claim construction brief.	
07/23/21	A M Nicolais	1.70
	Edits/revisions to Collegium opening claim construction brief re 434 patent (.5); citation and caselaw check re same (1.1); preparing paper for filing (.1).	
07/23/21	K I Nix	2.80
	E-mails with D. Rosen and J. Darensbourg regarding [REDACTED] and work regarding same (.8); reviewed revised draft claim construction brief (1.0); work regarding [REDACTED] and revised draft memorandum (1.0).	
07/23/21	J J Normile	1.80
	Attention to [REDACTED] (1.0); review Collegium claim construction brief(.80).	
07/24/21	K McCarthy	0.50
	Review/analyze parties opening claim construction briefs and communicate with client regarding [REDACTED] [REDACTED] (0.5).	
07/25/21	K I Nix	1.70
	Studied [REDACTED] studied Collegium claim construction brief.	
07/26/21	G J Larosa	1.50
	Review/analyze [REDACTED]; and conferred in firm and with client regarding same.	
07/26/21	K McCarthy	5.00
	Prepare for and participate in teleconference [REDACTED] [REDACTED] (0.5); review/analyze [REDACTED] [REDACTED] (0.9); draft/revise [REDACTED] and communicate with client and co-counsel regarding same (0.6); review [REDACTED] (0.5); draft/revise [REDACTED]	

**JONES DAY**

305158.610005

Page: 12

October 15, 2021

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 210903858

[REDACTED] (0.5); draft/revise [REDACTED] (1.5); attention to miscellaneous internal correspondence regarding [REDACTED] (0.5).

07/26/21 K I Nix 1.20  
Work regarding [REDACTED] and reviewed emails and notes with D. Rosen.

07/26/21 J J Normile 2.00  
Preparation for and participation in weekly team teleconference with B. Koch, R. Silbert, R. Inz and P. Hendler (.50); attention to [REDACTED] (.75); attention to various outstanding discovery matters (0.75).

07/27/21 G J Larosa 1.50  
Plan and prepare for [REDACTED] (1.0); reviewed [REDACTED] (.5).

07/27/21 K McCarthy 6.00  
Draft/revise responses to Collegium's fourth set of interrogatories and review/analyze documents and correspondence related to same (2.0); draft/revise discovery letter response (1.2); review/analyze Collegium's prior discovery responses and the parties' prior discovery correspondence regarding outstanding discovery deficiencies (1.3); attention to [REDACTED] (0.5); attention to [REDACTED] (0.6); draft/revise responses to Collegium's fourth set of RFPs(0.4).

07/27/21 A M Nicolais 4.30  
Drafting responses to Collegium's 4th set of RFPs (3.2); communication ((in firm with K. McCarthy re [REDACTED] (.2); reviewing Collegium 434 memo iso claim construction (.5) [REDACTED] (.4).

07/27/21 K I Nix 3.30  
Studied and revised draft memorandum [REDACTED] and email to S. Anwar regarding same (1.3); e-mails to K. McCarthy and A. Nicolais regarding [REDACTED] (.7); studied [REDACTED] (1.3).

07/27/21 J J Normile 0.80  
Preparation for and participation in teleconference with B. Koch, G. LaRosa, A. Nicolais and P. Hendler regarding [REDACTED] (.80).

07/28/21 J J Darensbourg 1.70  
Manage shared database for attorneys of correspondence and pleadings regarding both parties' Preliminary Claim Construction Briefs for the '434 patent and accompanying exhibits and Patheon's response to Purdue's subpoena to produce documents.

07/28/21 K McCarthy 2.50  
Draft/revise response to Collegium discovery letter [REDACTED] (1.0); draft/revise Purdue's August 9 discovery responses and review materials related to same (1.0) attention to miscellaneous case correspondence (0.5).

07/28/21 A M Nicolais 0.90  
Edits/revisions to draft RFP responses to Collegium's fourth RFPs and incorporating P. Hendler edits re same (.9).

**JONES DAY**

305158.610005

Page: 13

October 15, 2021

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 210903858

07/28/21	K I Nix	3.20
Worked on [REDACTED] and memorandum summarizing legal analysis (2.6); worked on draft responses to Collegium's RFAs (.4); work regarding [REDACTED] (.2).		
07/29/21	M M Jackson	1.50
Research to [REDACTED] using the web for K. McCarthy.		
07/29/21	K McCarthy	6.50
Draft/revise response to Collegium discovery letter and communicate internally regarding same (2.0); coordinate research [REDACTED] and review/analyze obtained documents (1.0); perform legal research [REDACTED] (2.0); attention to miscellaneous internal and client correspondence (0.6); review/analyze Patheon's subpoena response and communicate with team regarding review of same (0.4); communicate internally and with client regarding document discovery issues (0.5).		
07/29/21	A M Nicolais	3.30
Communication in firm with K. McCarthy re Collegium action items (.3); research [REDACTED] (2.0); drafting summary re same (.5); review/analyze Patheon response to Subpoena (.5).		
07/29/21	K I Nix	4.60
Studied and revised draft letter to C. Pinahs (1.2); studied and revised draft responses to Collegium RFPs nos. 90-115, and email to A. Nicolais and P. Hendler regarding same (2.0); attention to [REDACTED] (.8); revised memorandum summarizing legal research regarding [REDACTED] and e-mails with S. Anwar regarding same (.6).		
07/29/21	J J Normile	3.30
Review and revise [REDACTED] (1.5); review of [REDACTED] (.50); review of Purdue's claim construction brief (.80).		
07/30/21	J J Darensbourg	2.10
Manage files received by D Rosen for review by K Nix and document production received by Collegium.		
07/30/21	G J Larosa	2.00
Draft/revise [REDACTED] and conferred in firm regarding same.		
07/30/21	K McCarthy	3.00
Attention to internal and opposing counsel correspondence regarding Collegium's document production (0.5); review [REDACTED] (1.0); review [REDACTED] (1.5).		
07/30/21	A M Nicolais	3.00
Draft/revise reply claim construction brief (1.0); researching supporting caselaw re same (2.0).		

**JONES DAY**

305158.610005

Page: 14

October 15, 2021

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 210903858

07/30/21	K I Nix	4.20
Worked on and finalized memo summarizing legal research and analysis of [REDACTED] (.5); studied new documents regarding [REDACTED] (.7); work regarding [REDACTED] (1.3); reviewed and revised draft letter to C. Pinahs (.6); teleconference with D. Rosen regarding discovery issues, and follow up regarding same (1.1).		
07/30/21	J J Normile	1.50
Attention to various discovery issues including preparation of responses to Collegium's outstanding discovery requests and supplementation of earlier discovery responses.		
07/31/21	K McCarthy	6.00
Draft/revise response to Collegium discovery letter (0.8); review/analyze [REDACTED] (0.8); draft/revise [REDACTED] (1.2); draft/revise [REDACTED] (2.2); attention to case files and case correspondence regarding claim construction and discovery issues (1.0).		
Total		303.60

305158.610005

Page: 15

October 15, 2021

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 210903858

## Disbursement Detail

<i>Date</i>	<i>Timekeeper/Fee Earner Name</i>	<i>Location</i>	<i>Amount</i>	<i>Total</i>
<b>FEDERAL EXPRESS CHARGES</b>				
07/02/21	T E Solomon	NYC	42.37	
Vendor: Federal Express Corporation Invoice#: 743238845 Date: 7/12/2021 - - Ship To: Gasper LaROSA, Ship				
Dt: 07/02/21 Airbill: 281055511810				
07/02/21	T E Solomon	NYC	47.47	
Vendor: Federal Express Corporation Invoice#: 743238845 Date: 7/12/2021 - - Ship To: JOHN NORMILE, Ship				
Dt: 07/02/21 Airbill: 281055354450				
<b>Federal Express Charges Subtotal</b>				<b>89.84</b>
<b>Total Disbursements and Charges</b>				<b>USD 89.84</b>

**JONES DAY**

**New York Office**  
250 Vesey Street  
New York, NY 10281-1047  
(212) 326-3939

**Federal Identification Number: 34-0319085**

October 15, 2021

305158.610028  
Invoice: 210903859

Purdue Pharma L.P.  
Attention: Bruce J. Koch, Esq.  
Chief Patent Counsel  
One Stamford Forum  
Stamford, CT 06901

For legal services rendered for the period through July 31, 2021:

Accord Healthcare Inc.	USD	17,342.00
Less 13% Discount		<u>(2,254.46)</u>
Total Billed Fees	USD	15,087.54
<b>TOTAL</b>	<b>USD</b>	<b><u>15,087.54</u></b>

Please remit payment to:

**ACH Transfer (preferred)**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089

**Wire Transfer**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089  
Swift Code: CITIUS33

PLEASE REFERENCE 305158 610028/210903859 WITH YOUR PAYMENT

Pg 31 of 41  
**JONES DAY**

305158.610028

Page: 2

October 15, 2021

Accord Healthcare Inc.

Invoice: 210903859

## Timekeeper/Fee Earner Summary

	<i>Hours</i>	<i>Rate</i>	<i>Amount</i>
Partner			
J J Normile	7.20	1,250.00	9,000.00
Of Counsel			
K I Nix	0.30	1,180.00	354.00
Associate			
K McCarthy	7.80	715.00	5,577.00
A M Nicolais	3.20	655.00	2,096.00
Paralegal			
J J Darensbourg	0.90	350.00	315.00
<b>Total</b>	<b>19.40</b>	<b>USD</b>	<b>17,342.00</b>

**JONES DAY**

305158.610028

Page: 3

October 15, 2021

Accord Healthcare Inc.

Invoice: 210903859

## Fee Detail

<i>Date of Service</i>	<i>Timekeeper/Fee Earner Name</i>	<i>Hours</i>
07/01/21	K McCarthy	1.00
Draft/revise 1st set of RFPs and 1st set of Interrogatories to Accord (0.5); attention to case files and correspondence (0.5).		
07/01/21	A M Nicolais	0.90
Final edits/revisions/review of initial Rgs and RFP requests to Accord (.9).		
07/01/21	J J Normile	1.00
Review and revise initial discovery requests and various correspondence regarding same.		
07/02/21	K McCarthy	0.50
Attention to case file and correspondence regarding, e.g., Purdue's recently-served discovery requests (0.5).		
07/02/21	J J Normile	0.50
Review of [REDACTED]		
07/10/21	J J Normile	1.00
Preliminary review [REDACTED]		
07/12/21	K McCarthy	1.50
Review/analyze Accord's initial invalidity contentions (0.5); draft/revise [REDACTED] (1.0)		
07/12/21	A M Nicolais	0.60
Review/analyze Accord invalidity contentions (.6).		
07/12/21	J J Normile	2.00
Continued review [REDACTED] (1.0); attention to [REDACTED] (1.0).		
07/13/21	K McCarthy	1.50
Review/analyze [REDACTED] (1.0); [REDACTED] (0.5).		
07/14/21	K McCarthy	1.50
Draft/revise [REDACTED] (0.6); attention to case files and correspondence regarding Accord's invalidity contentions (0.4); draft/revise third party subpoena (0.5).		
07/14/21	J J Normile	1.10
Review [REDACTED] (.80); [REDACTED] (.30).		



Pg 33 of 41  
**JONES DAY**

305158.610028

Page: 4

October 15, 2021

Accord Healthcare Inc.

Invoice: 210903859

<i>Date of Service</i>	<i>Timekeeper/Fee Earner Name</i>	<i>Hours</i>
07/15/21	J J Darensbourg Manage shared database for attorneys of both parties' discovery and Defendant's Initial Invalidity Contentions.	0.60
07/15/21	J J Normile Attention to [REDACTED]	0.50
07/16/21	A M Nicolais Final review and preparing/coordinating service of proposed terms for construction (.3).	0.30
07/16/21	J J Normile Attention to [REDACTED]	0.80
07/19/21	K McCarthy Prepare for and participate in weekly client call regarding litigation status updates (0.7), including reviewing and providing comments to draft Purdue litigation tracker (0.1).	0.80
07/19/21	J J Normile Review of [REDACTED]	0.30
07/21/21	J J Darensbourg Manage shared database for attorneys of proposed claim terms and constructions.	0.30
07/26/21	K McCarthy Draft/revise [REDACTED] and communicate with A. Nicolais regarding same (0.5).	0.50
07/27/21	K McCarthy Draft/revise [REDACTED] and communicate internally regarding same (0.5).	0.50
07/27/21	A M Nicolais Drafting [REDACTED] (.7); communication in firm re same (.1).	0.80
07/28/21	A M Nicolais Edits/revisions to [REDACTED] incorporating edit/revisions from P. Hendler re same.	0.60
07/29/21	K I Nix Reviewed [REDACTED]	0.30
<b>Total</b>		<b>19.40</b>

**JONES DAY**

**New York Office**  
250 Vesey Street  
New York, NY 10281-1047  
(212) 326-3939

**Federal Identification Number: 34-0319085**

October 15, 2021

305158.640002  
Invoice: 210903860

Purdue Pharma L.P.  
Attention: Bruce J. Koch, Esq.  
Chief Patent Counsel  
One Stamford Forum  
Stamford, CT 06901

For legal services rendered for the period through July 31, 2021:

Strategic Corporate Advice	USD	11,944.50
Less 13% Discount		<u>(1,552.79)</u>
Total Billed Fees	USD	10,391.71
<b>TOTAL</b>	<b>USD</b>	<b><u>10,391.71</u></b>

Please remit payment to:

**ACH Transfer (preferred)**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089

**Wire Transfer**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089  
Swift Code: CITIUS33

Pg 35 of 41  
**JONES DAY**

305158.640002

Page: 2

October 15, 2021

Strategic Corporate Advice

Invoice: 210903860

## Timekeeper/Fee Earner Summary

	<i>Hours</i>	<i>Rate</i>	<i>Amount</i>
Partner			
D T Moss	0.20	1,075.00	215.00
J J Normile	1.50	1,250.00	1,875.00
Associate			
K McCarthy	12.50	715.00	8,937.50
A M Nicolais	1.40	655.00	917.00
<b>Total</b>	<b>15.60</b>	<b>USD</b>	<b>11,944.50</b>

Pg 36 of 41  
**JONES DAY**

305158.640002

Page: 3

October 15, 2021

Strategic Corporate Advice

Invoice: 210903860

## Fee Detail

<i>Date of Service</i>	<i>Timekeeper/Fee Earner Name</i>	<i>Hours</i>
07/06/21	K McCarthy	2.00
	Draft/revise [REDACTED] (0.9); draft/revise [REDACTED] (0.6); draft/revise [REDACTED] and communicate with C. Buck regarding same (0.5).	
07/07/21	K McCarthy	1.00
	Draft/revise [REDACTED] and ((communicate with C. Buck and J. Normile regarding same)) (1.0).	
07/09/21	K McCarthy	0.50
	Draft/revise [REDACTED] and ((communicate with C. Buck regarding same)) (0.5).	
07/12/21	A M Nicolais	0.80
	Draft/revise weekly Purdue updates (.4); weekly Purdue meeting (.4).	
07/14/21	K McCarthy	2.00
	Draft/revise [REDACTED] and communicate internally regarding same (2.0).	
07/14/21	D T Moss	0.20
	Communicate with ((J. Normile regarding [REDACTED])	
07/19/21	K McCarthy	0.70
	Draft/revise [REDACTED] and communicate internally regarding same (0.7).	
07/19/21	A M Nicolais	0.60
	Preparing weekly Purdue litigation updates (.3); weekly Purdue meeting (.3).	
07/20/21	K McCarthy	0.80
	Draft/revise [REDACTED] and communicate internally regarding same (0.8).	
07/25/21	K McCarthy	3.00
	Draft/revise [REDACTED] and communicate internally regarding same (3.0).	
07/26/21	K McCarthy	2.50
	Draft/revise [REDACTED] and communicate with J. Normile regarding same (2.5).	
07/28/21	J J Normile	1.50
	Preparation for and participation in teleconference with DPW and Purdue regarding [REDACTED] (1.5).	

**JONES DAY**

305158.640002

Page: 4

October 15, 2021

Strategic Corporate Advice

Invoice: 210903860

*Date of Service*

*Timekeeper/Fee Earner Name*

*Hours*

**Total**

---

**15.60**

**JONES DAY**

**New York Office**

250 Vesey Street

New York, NY 10281-1047

**(212) 326-3939**

**Federal Identification Number: 34-0319085**

October 15, 2021

305158.999007

Invoice: 210903861

Purdue Pharma L.P.

Attention: Bruce J. Koch, Esq.

Chief Patent Counsel

One Stamford Forum

Stamford, CT 06901

For legal services rendered for the period through July 31, 2021:

Retention Matters	USD	14,625.00
Less 13% Discount		<u>(1,901.25)</u>
Total Billed Fees	USD	12,723.75
<b>TOTAL</b>	<b>USD</b>	<b><u>12,723.75</u></b>

Please remit payment to:

**ACH Transfer (preferred)**

Citibank, N.A.

New York, NY

Account Name: Jones Day

Account No: 37026407

ABA No: 021000089

**Wire Transfer**

Citibank, N.A.

New York, NY

Account Name: Jones Day

Account No: 37026407

ABA No: 021000089

Swift Code: CITIUS33

PLEASE REFERENCE 305158 999007/210903861 WITH YOUR PAYMENT

Pg 39 of 41  
**JONES DAY**

305158.999007

Page: 2

October 15, 2021

Retention Matters

Invoice: 210903861

## Timekeeper/Fee Earner Summary

	<i>Hours</i>	<i>Rate</i>	<i>Amount</i>
Partner			
J J Normile	7.30	1,250.00	9,125.00
Associate			
C Buck	8.80	575.00	5,060.00
Paralegal			
M M Melvin	1.10	400.00	440.00
<b>Total</b>	<b>17.20</b>	<b>USD</b>	<b>14,625.00</b>

Pg 40 of 41  
**JONES DAY**

305158.999007

Page: 3

October 15, 2021

Retention Matters

Invoice: 210903861

## Fee Detail

<i>Date of Service</i>	<i>Timekeeper/Fee Earner Name</i>	<i>Hours</i>
07/05/21	C Buck Revise excel for Fifth Interim Fee Application.	2.40
07/05/21	C Buck Draft Fifth Interim Fee Application.	2.30
07/06/21	J J Normile Attention to preparation of Jones Day fifth interim fee petition and review of relevant budgets regarding same.	0.80
07/07/21	C Buck Prepare for and attend call to discuss Fifth Interim Fee Application with J. Normile and K. McCarthy.	0.30
07/07/21	J J Normile Review and revise Jones Day's fifth interim fee application [REDACTED].	1.00
07/11/21	C Buck Revise Fifth Interim Fee Application.	0.20
07/12/21	C Buck Revise Fifth Interim Fee Application.	0.50
07/12/21	J J Normile Attention to preparation of Jones Day's Fifth Interim Fee Application.	0.50
07/13/21	C Buck Revise interim fee application [REDACTED].	0.40
07/13/21	J J Normile Attention to finalizing Jones Day's Fifth Interim Fee Application and [REDACTED].	1.50
07/14/21	J J Normile Attention to preparation of Jones Day's Fifth Interim Fee Petition [REDACTED].	0.80
07/15/21	C Buck Finalize Fifth Interim Fee application for filing.	1.60
07/15/21	M M Melvin Gather the February through May fee statements and assemble to prepare an exhibit to Jones Day's fifth interim fee application (0.40); forward compiled exhibits to C. Buck to review (0.10); assemble exhibits with the fee application (0.10); send the same to C. Buck for review (0.10); review and e-file Jones Day's fifth interim fee application (0.30); forward a filed copy to C. Buck (0.10).	1.10
07/15/21	J J Normile Various correspondence with K. McCarthy regarding [REDACTED] and review of same (.80); finalizing Jones Day's Fifth Interim Fee Petition [REDACTED] (.80); review of [REDACTED] (.80).	2.40



Pg 41 of 41  
**JONES DAY**

305158.999007

Page: 4

October 15, 2021

Retention Matters

Invoice: 210903861

<i>Date of Service</i>	<i>Timekeeper/Fee Earner Name</i>	<i>Hours</i>
07/19/21	J J Normile Review of various correspondence relating to [REDACTED]	0.30
07/27/21	C Buck Revise June invoices for compliance with UST guidelines.	1.10
<b>Total</b>		<hr/> <b>17.20</b>